Diagnosis and treatment of neurocysticercosis

被引:153
作者
Nash, Theodore E. [2 ]
Garcia, Hector H. [1 ]
机构
[1] Inst Nacl Ciencias Neurol, Cysticercosis Unit, Lima, Peru
[2] NIAID, Gastrointestinal Parasites Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HIGH-DOSE PRAZIQUANTEL; LINKED IMMUNOELECTROTRANSFER BLOT; SOLITARY CYSTICERCUS GRANULOMA; TAENIA-SOLIUM CYSTICERCOSIS; ALBENDAZOLE THERAPY; CEREBRAL CYSTICERCOSIS; CALCIFIED NEUROCYSTICERCOSIS; PERILESIONAL GLIOSIS; IMMUNOSORBENT-ASSAY; CEREBROSPINAL-FLUID;
D O I
10.1038/nrneurol.2011.135
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neurocysticercosis is a parasitic disease caused by the larval (cystic) form of the pork cestode tapeworm, Taenia solium, and is a major cause of acquired seizures and epilepsy worldwide. Development of sensitive and specific diagnostic methods, particularly CT and MRI, has revolutionized our knowledge of the burden of cysticercosis infection and disease, and has led to the development of effective antihelminthic treatments for neurocysticercosis. The importance of calcified granulomas with perilesional edema as foci of seizures and epilepsy in populations where neurocysticercosis is endemic is newly recognized, and indicates that treatment with anti-inflammatory agents could have a role in controlling or preventing epilepsy in these patients. Importantly, neurocysticercosis is one of the few diseases that could potentially be controlled or eliminated-an accomplishment that would prevent millions of cases of epilepsy. This Review examines the rationale for treatment of neurocysticercosis and highlights the essential role of inflammation in the pathogenesis of disease, the exacerbation of symptoms that occurs as a result of antihelminthic treatment, and the limitations of current antihelminthic and anti-inflammatory treatments. Nash, T. E. & Garcia, H. H. Nat. Rev. Neurol. 7, 584-594 (2011); published online 13 September 2011; doi:10.1038/nrneurol.2011.135
引用
收藏
页码:584 / 594
页数:11
相关论文
共 118 条
[1]  
ADAMOLEKUM B, 1994, EPILEPSIA, V35, P89
[2]   Severe forms of neurocysticercosis [J].
Agapejev, S ;
DaSilva, MD ;
Ueda, AK .
ARQUIVOS DE NEURO-PSIQUIATRIA, 1996, 54 (01) :82-93
[3]  
Antoniuk S, 2006, Rev Neurol, V42 Suppl 3, pS97
[4]   EXTRAPARENCHYMAL NEUROCYSTICERCOSIS - REPORT OF 5 CASES AND REVIEW OF MANAGEMENT [J].
BANDRES, JC ;
WHITE, AC ;
SAMO, T ;
MURPHY, EC ;
HARRIS, RL .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (05) :799-811
[5]   Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial [J].
Baranwal, AK ;
Singhi, PD ;
Khandelwal, N ;
Singhi, SC .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (08) :696-700
[6]   Endoscopic removal of cysticercal cysts within the fourth ventricle - Technical note [J].
Bergsneider, M .
JOURNAL OF NEUROSURGERY, 1999, 91 (02) :340-345
[7]   Endoscopic management of cysticercal cysts within the lateral and third ventricles [J].
Bergsneider, M ;
Holly, LT ;
Lee, JH ;
King, WA ;
Frazee, JG .
JOURNAL OF NEUROSURGERY, 2000, 92 (01) :14-23
[8]   THE RACEMOSE FORM OF CEREBRAL CYSTICERCOSIS [J].
BICKERSTAFF, ER ;
CLOAKE, PCP ;
HUGHES, B ;
SMITH, WT .
BRAIN, 1952, 75 (01) :1-18
[9]  
BITTENCOURT PRM, 1990, ACTA NEUROL SCAND, V82, P28, DOI 10.1111/j.1600-0404.1990.tb01583.x
[10]   PHENYTOIN AND CARBAMAZEPINE DECREASE ORAL BIOAVAILABILITY OF PRAZIQUANTEL [J].
BITTENCOURT, PRM ;
GRACIA, CM ;
MARTINS, R ;
FERNANDES, AG ;
DIEKMANN, HW ;
JUNG, W .
NEUROLOGY, 1992, 42 (03) :492-496